Can a triple-drug attack shrink hard-to-treat breast cancer?

NCT ID NCT02252887

Completed Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jul 24, 2026 · Last updated Jul 24, 2026

Summary

This phase II trial is testing whether adding two HER2-targeted drugs (trastuzumab and pertuzumab) to the chemotherapy gemcitabine can help people with metastatic HER2-positive breast cancer who have already received similar treatments. The study aims to see how long the cancer stays under control and how safe the combination is. Participants must have stage IV HER2-positive breast cancer and have had prior trastuzumab/pertuzumab-based therapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: a combination of gemcitabine (chemotherapy), trastuzumab, and pertuzumab (HER2-targeted drugs)
What this could lead to: If effective, this combination could offer a new treatment option for people with advanced HER2-positive breast cancer who have already received similar targeted therapies.
What could go wrong: This is a small, early-phase trial, so the combination may not work better than existing options. Side effects from chemotherapy and targeted drugs are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC HER2-POSITIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HER2 positive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC HER2-POSITIVE BREAST CANCER

Contacts and locations

Show contact details

Locations

Hartford Healthcare Cancer Institute @ Hartford Hospital

Hartford, Connecticut, 06102, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Memorial Sloan Kettering Monmouth

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Westchester

Harrison, New York, 10604, United States
Memorial Sloan Kettering at Basking Ridge

Basking Ridge, New Jersey, 07920, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.